Stock comparison
Merck & Co., Inc. is 203.6x more valuable than MoonLake Immunotherapeutics by market capitalization ($305.12 B vs $1.50 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 203.6x more valuable than MoonLake Immunotherapeutics by market capitalization ($305.12 B vs $1.50 B).
Market value leader
MRK
Merck & Co., Inc. is 203.6x more valuable than MoonLake Immunotherapeutics by market capitalization ($305.12 B vs $1.50 B).
Profit leader
MRK
MLTX: -$227.32M vs MRK: $18.25B.
| Metric | MLTX | MRK |
|---|---|---|
| Market cap | $1.50 B | $305.12 B |
| US-listed rank | #2357 | #44 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$227.32M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.7x |
| SEC filings | 296 | 1,000 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 203.6x more valuable than MoonLake Immunotherapeutics by market capitalization ($305.12 B vs $1.50 B).
Full pages: MoonLake Immunotherapeutics and Merck & Co., Inc., or browse the full rankings.